Miaderm vs Aquaphor for Radiation Dermatitis in Breast Cancer Patients

This clinical trial aims to compare the effectiveness of two topical treatments, Miaderm and Aquaphor, in managing radiation dermatitis. Radiation dermatitis is a common side effect experienced by breast cancer patients undergoing external beam radiation therapy (EBRT) to the breast or chest wall. The study's primary goal is to determine which of these two treatments is more effective in preventing or treating this condition. The trial is particularly important as it could help improve the quality of life for breast cancer patients undergoing radiation therapy, by identifying a more effective treatment for radiation dermatitis. Participants in this study are randomly assigned to one of two groups. The first group applies Aquaphor twice daily, starting from the first day of radiation therapy, to the area receiving radiation, with the exception of the four hours before treatment. This continues until two weeks after the completion of radiation therapy. The second group follows the same procedure but uses Miaderm instead of Aquaphor. After the completion of the treatment, patients are followed up at two weeks and then between 90 to 120 days. The study measures the effectiveness of these treatments by assessing the presence of acute radiation dermatitis using the Radiation Therapy Oncology Group / European Organization for Research and Treatment of Cancer (RTOG/EORTC toxicity score). The analysis will take into account the repeated assessments for each patient to understand the association between the treatment and the outcome.